Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6388.0000 -48.50 (-0.75%)
NSE Jan 14, 2026 12:30 PM
Volume: 278.5K
 

6388.00
-0.75%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 6% YoY to | 1038 crore (I-direct estimate: | 957 crore) driven by growth across segments EBITDA margins declined 724 bps YoY to 31.4% (I-direct estimate: 36%), impacted mainly by lower gross margins (60.7% in Q3FY18 vs. 64.1% in Q3FY17), higher remediation cost & forex loss of | 16 crore in Q3FY18 vs. gain of | 0.7 crore in Q3FY17. Subsequently, EBITDA declined 14% YoY to | 326 crore (I-direct estimates of | 345 crore)...
Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr
More from Divi's Laboratories Ltd.
Recommended